HRP20110503T1 - MODIFICIRANE FUZIJE IZMEĐU TOPIVOG FGF RECEPTORA I Fc, S POBOLJŠANOM BIOLOŠKOM AKTIVNOŠĆU - Google Patents
MODIFICIRANE FUZIJE IZMEĐU TOPIVOG FGF RECEPTORA I Fc, S POBOLJŠANOM BIOLOŠKOM AKTIVNOŠĆU Download PDFInfo
- Publication number
- HRP20110503T1 HRP20110503T1 HR20110503T HRP20110503T HRP20110503T1 HR P20110503 T1 HRP20110503 T1 HR P20110503T1 HR 20110503 T HR20110503 T HR 20110503T HR P20110503 T HRP20110503 T HR P20110503T HR P20110503 T1 HRP20110503 T1 HR P20110503T1
- Authority
- HR
- Croatia
- Prior art keywords
- fgf receptor
- fusion
- soluble
- modified fusion
- soluble fgf
- Prior art date
Links
- 230000004071 biological effect Effects 0.000 title 1
- 108091008794 FGF receptors Proteins 0.000 claims abstract 56
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 claims abstract 56
- 230000004927 fusion Effects 0.000 claims abstract 46
- 125000005629 sialic acid group Chemical group 0.000 claims abstract 3
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract 2
- 239000012634 fragment Substances 0.000 claims abstract 2
- 102000018358 immunoglobulin Human genes 0.000 claims abstract 2
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 5
- 229940127089 cytotoxic agent Drugs 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims 4
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 4
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims 4
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims 4
- 230000004988 N-glycosylation Effects 0.000 claims 4
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims 4
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims 4
- 102000002262 Thromboplastin Human genes 0.000 claims 4
- 108010000499 Thromboplastin Proteins 0.000 claims 4
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 claims 2
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 claims 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims 2
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims 2
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims 2
- 201000008808 Fibrosarcoma Diseases 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 101800004937 Protein C Proteins 0.000 claims 2
- 102000017975 Protein C Human genes 0.000 claims 2
- 229940096437 Protein S Drugs 0.000 claims 2
- 102000029301 Protein S Human genes 0.000 claims 2
- 108010066124 Protein S Proteins 0.000 claims 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 2
- 101800001700 Saposin-D Proteins 0.000 claims 2
- 201000010208 Seminoma Diseases 0.000 claims 2
- HRNQLKCLPVKZNE-CIUDSAMLSA-N Ser-Ala-Leu Chemical group [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O HRNQLKCLPVKZNE-CIUDSAMLSA-N 0.000 claims 2
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims 2
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 230000002378 acidificating effect Effects 0.000 claims 2
- 229940100198 alkylating agent Drugs 0.000 claims 2
- 239000002168 alkylating agent Substances 0.000 claims 2
- 230000002491 angiogenic effect Effects 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 230000000340 anti-metabolite Effects 0.000 claims 2
- 239000002256 antimetabolite Substances 0.000 claims 2
- 229940100197 antimetabolite Drugs 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- 230000022131 cell cycle Effects 0.000 claims 2
- 229940126864 fibroblast growth factor Drugs 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 239000002944 hormone and hormone analog Substances 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 229910052697 platinum Inorganic materials 0.000 claims 2
- 230000000861 pro-apoptotic effect Effects 0.000 claims 2
- 229960000856 protein c Drugs 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 2
- 230000019491 signal transduction Effects 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 229940063683 taxotere Drugs 0.000 claims 2
- 210000001685 thyroid gland Anatomy 0.000 claims 2
- 102000003390 tumor necrosis factor Human genes 0.000 claims 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010023347 Keratoacanthoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical group C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims 1
- 102100035838 Lactosylceramide 4-alpha-galactosyltransferase Human genes 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 108010070808 UDP-galactose-lactosylceramide alpha 1-4-galactosyltransferase Proteins 0.000 claims 1
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 230000001946 anti-microtubular Effects 0.000 claims 1
- 229940044684 anti-microtubule agent Drugs 0.000 claims 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 239000012829 chemotherapy agent Substances 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000003325 follicular Effects 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 208000007538 neurilemmoma Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 125000005630 sialyl group Chemical group 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 208000001608 teratocarcinoma Diseases 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06291824 | 2006-11-28 | ||
| EP07290042 | 2007-01-11 | ||
| PCT/IB2007/004354 WO2008065543A2 (en) | 2006-11-28 | 2007-11-28 | Modified soluble fgf receptor fc fusions with improved biological activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110503T1 true HRP20110503T1 (hr) | 2011-08-31 |
Family
ID=39431092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110503T HRP20110503T1 (hr) | 2006-11-28 | 2011-07-06 | MODIFICIRANE FUZIJE IZMEĐU TOPIVOG FGF RECEPTORA I Fc, S POBOLJŠANOM BIOLOŠKOM AKTIVNOŠĆU |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US8119770B2 (es) |
| EP (1) | EP2092069B2 (es) |
| JP (1) | JP2010510801A (es) |
| KR (1) | KR20090102769A (es) |
| AR (1) | AR063975A1 (es) |
| AT (1) | ATE509106T1 (es) |
| AU (1) | AU2007326985C1 (es) |
| BR (1) | BRPI0719290A2 (es) |
| CA (1) | CA2668932A1 (es) |
| CL (1) | CL2007003411A1 (es) |
| CO (1) | CO6190564A2 (es) |
| CR (1) | CR10777A (es) |
| CY (1) | CY1112435T1 (es) |
| DK (1) | DK2092069T3 (es) |
| EA (1) | EA018700B1 (es) |
| EC (1) | ECSP099361A (es) |
| GT (1) | GT200900137A (es) |
| HR (1) | HRP20110503T1 (es) |
| IL (1) | IL198480A0 (es) |
| MA (1) | MA31143B1 (es) |
| MX (1) | MX2009005692A (es) |
| MY (1) | MY145914A (es) |
| NI (1) | NI200900097A (es) |
| NO (1) | NO20092414L (es) |
| PE (1) | PE20081250A1 (es) |
| PL (1) | PL2092069T3 (es) |
| PT (1) | PT2092069E (es) |
| RS (1) | RS51911B (es) |
| SI (1) | SI2092069T1 (es) |
| SV (1) | SV2009003272A (es) |
| TN (1) | TN2009000184A1 (es) |
| TW (1) | TW200839012A (es) |
| WO (1) | WO2008065543A2 (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2520654T3 (pl) | 2003-08-26 | 2017-08-31 | The Regents Of The University Of Colorado, A Body Corporate | Inhibitory aktywności proteazy serynowej i ich zastosowanie w sposobach i kompozycjach do leczenia zakażeń bakteryjnych |
| AU2006272759B2 (en) | 2005-07-22 | 2012-01-12 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with FGFR fusion proteins |
| RU2509774C2 (ru) | 2008-08-04 | 2014-03-20 | Файв Прайм Терапьютикс, Инк. | Мутеины кислотной зоны внеклеточного домена рецептора фактора роста фибробластов |
| WO2011034940A1 (en) | 2009-09-15 | 2011-03-24 | Five Prime Therapeutics, Inc. | Hair growth methods using fgfr4 extracellular domains |
| LT2498799T (lt) * | 2009-11-13 | 2016-11-10 | Five Prime Therapeutics, Inc. | Fgfr1 ekstraląstelinio domeno baltymų panaudojimas gydymui vėžio su nuo ligando priklausančiomis, aktyvuojančiomis fgfr2 mutacijomis |
| US8685931B2 (en) | 2009-12-17 | 2014-04-01 | Five Prime Therapeutics, Inc. | Hair growth methods using FGFR3 extracellular domains |
| FR2958936A1 (fr) | 2010-04-14 | 2011-10-21 | Sanofi Aventis | Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs |
| US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| AU2015258172B2 (en) * | 2010-11-15 | 2017-01-12 | Five Prime Therapeutics, Inc. | Fgfr1 extracellular domain combination therapies |
| EP2640406A1 (en) * | 2010-11-15 | 2013-09-25 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins |
| US8951972B2 (en) * | 2010-12-09 | 2015-02-10 | Five Prime Therapeutics, Inc. | FGFR1 extracellular domain combination therapies for lung cancer |
| CN103703021A (zh) | 2010-12-23 | 2014-04-02 | 赛诺菲 | 用于治疗肝癌的Robo1-Fc融合蛋白 |
| AR085302A1 (es) * | 2011-02-24 | 2013-09-18 | Sanofi Sa | Metodo de produccion de anticuerpos sialilados |
| CN102219859B (zh) | 2011-05-20 | 2012-09-12 | 烟台荣昌生物工程有限公司 | 拮抗血管新生诱导因子的融合蛋白及其用途 |
| CN102219860B (zh) * | 2011-05-20 | 2012-09-12 | 烟台荣昌生物工程有限公司 | FGFR-Fc融合蛋白及其用途 |
| JP6216921B2 (ja) | 2011-06-24 | 2017-11-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ | アルファ−１抗トリプシン融合分子のための組成物、方法および使用 |
| UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
| EP2780033B1 (en) | 2011-11-14 | 2019-05-08 | Five Prime Therapeutics, Inc. | An fgfr1 extracellular domain for use in the treatment of cancer with an fgfr1 gene amplification |
| US10478508B2 (en) | 2012-01-10 | 2019-11-19 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
| WO2014111744A1 (en) | 2013-01-16 | 2014-07-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders |
| CN105246511A (zh) | 2013-03-06 | 2016-01-13 | 豪夫迈·罗氏有限公司 | 治疗和预防癌症药物抗性的方法 |
| CN110256560A (zh) * | 2013-03-11 | 2019-09-20 | 建新公司 | 通过糖工程的位点特异性抗体-药物偶联 |
| US9957313B2 (en) | 2013-03-15 | 2018-05-01 | Remegen, Ltd. | FGFR-FC fusion proteins and the use thereof |
| KR102049990B1 (ko) | 2013-03-28 | 2019-12-03 | 삼성전자주식회사 | c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질 |
| EP3252171B8 (en) * | 2013-05-23 | 2021-12-15 | Five Prime Therapeutics, Inc. | Methods of treating cancer |
| HUE043815T2 (hu) | 2013-08-01 | 2019-09-30 | Five Prime Therapeutics Inc | Fukózmentes FGFR2IIIB elleni antitestek |
| PL3129067T3 (pl) | 2014-03-19 | 2023-05-08 | Genzyme Corporation | Specyficzne dla miejsca glikomodyfikowanie ugrupowań celujących |
| CN107073121A (zh) | 2014-06-13 | 2017-08-18 | 基因泰克公司 | 治疗及预防癌症药物抗性的方法 |
| TWI791422B (zh) * | 2015-11-23 | 2023-02-11 | 美商戊瑞治療有限公司 | 用於癌症治療之單獨fgfr2抑制劑或與免疫刺激劑組合 |
| JP7299842B2 (ja) | 2017-05-16 | 2023-06-28 | ファイヴ プライム セラピューティクス インク | がん治療における化学療法剤と組み合わせた抗ｆｇｆｒ２抗体 |
| EP3512874A2 (en) | 2017-11-30 | 2019-07-24 | Grifols Diagnostic Solutions Inc. | Immunoassays and engineered proteins for monitoring antibody treatments to the immune checkpoint inhibitors pd1 and pd-l1 |
| CN111655717A (zh) * | 2018-01-26 | 2020-09-11 | 豪夫迈·罗氏有限公司 | IL-22 Fc融合蛋白及使用方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5288856A (en) | 1986-11-20 | 1994-02-22 | Pierre Amiguet | Method of isolating acid-stable, biologically active proteins |
| JP3040121B2 (ja) * | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| US5750375A (en) * | 1988-01-22 | 1998-05-12 | Zymogenetics, Inc. | Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions |
| US5147638A (en) | 1988-12-30 | 1992-09-15 | Oklahoma Medical Research Foundation | Inhibition of tumor growth by blockade of the protein C system |
| US5288855A (en) * | 1989-01-23 | 1994-02-22 | Farmitalia Carlo Erba | Extracellular form of the human fibroblast growth factor receptor |
| US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US5153310A (en) * | 1989-02-28 | 1992-10-06 | Du Pont Merck Pharmaceutical Company | Il-2 analogs containing n-linked glycosylation sites |
| ES2133271T3 (es) | 1989-07-06 | 1999-09-16 | Univ California | Receptores para factores de crecimiento de fibroblastos. |
| WO1991017183A1 (en) * | 1990-04-27 | 1991-11-14 | Takeda Chemical Industries, Ltd. | Proteins with fibroblast growth factor receptor activity |
| US5349053A (en) * | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
| JP3615220B2 (ja) | 1990-07-06 | 2005-02-02 | アヴェンティス ファーマシューティカルズ インコーポレイテッド | 繊維芽細胞生育因子受容体 |
| US5541087A (en) * | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
| US20020045207A1 (en) * | 1997-10-31 | 2002-04-18 | Lynne A. Krummen | Glycoprotein production process |
| ATE458007T1 (de) | 1998-04-20 | 2010-03-15 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
| US6656728B1 (en) * | 1999-02-08 | 2003-12-02 | Chiron Corporation | Fibroblast growth factor receptor-immunoglobulin fusion |
| US6612152B2 (en) * | 1999-05-01 | 2003-09-02 | James E. Keaton | Lifting, servicing, and diagnosing automobiles |
| US6656738B1 (en) * | 1999-11-17 | 2003-12-02 | Bae Systems Integrated Defense Solutions Inc. | Internal heater for preconcentrator |
| JP2004504016A (ja) * | 2000-06-30 | 2004-02-12 | マキシゲン・エイピーエス | ペプチド拡張されたグリコシル化ポリペプチド |
| HU231090B1 (hu) | 2000-10-06 | 2020-07-28 | Kyowa Kirin Co., Ltd. | Antitest-kompozíciót termelő sejt |
| WO2003074679A2 (en) * | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
| US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US20040259150A1 (en) * | 2002-04-09 | 2004-12-23 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa |
| JPWO2003085118A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物の製造方法 |
| DK2345671T3 (en) * | 2002-09-27 | 2016-02-15 | Xencor Inc | Optimized Fc variants and methods for their formation |
| JP2007525187A (ja) | 2003-05-16 | 2007-09-06 | レセプター・バイオロジクス・インコーポレイテッド | イントロン融合タンパク質、ならびにその同定方法および使用方法 |
| CA2542130A1 (en) * | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Cell genomically modified to produce polypeptides with an altered glycosylation pattern |
| DE102004022895A1 (de) | 2004-05-10 | 2005-12-08 | Adam Opel Ag | Schallabsorbierendes Verkleidungselement |
| CN101987870B (zh) | 2004-07-15 | 2013-07-03 | 赞科股份有限公司 | 优化的Fc变体 |
| US20060223147A1 (en) * | 2004-08-05 | 2006-10-05 | Kyowa Hakko Kogyo Co., Ltd., | Process for producing glycoprotein composition |
| WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
| EP1871808A2 (en) | 2005-03-31 | 2008-01-02 | Xencor, Inc. | Fc VARIANTS WITH OPTIMIZED PROPERTIES |
| US20060234347A1 (en) | 2005-04-13 | 2006-10-19 | Harding Thomas C | Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors |
| EP1746161A1 (en) * | 2005-07-20 | 2007-01-24 | Cytheris | Glycosylated IL-7, preparation and uses |
| AU2006272759B2 (en) * | 2005-07-22 | 2012-01-12 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with FGFR fusion proteins |
| DK1931709T3 (en) | 2005-10-03 | 2017-03-13 | Xencor Inc | FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES |
-
2007
- 2007-11-27 AR ARP070105241A patent/AR063975A1/es not_active Application Discontinuation
- 2007-11-27 CL CL200703411A patent/CL2007003411A1/es unknown
- 2007-11-27 PE PE2007001663A patent/PE20081250A1/es not_active Application Discontinuation
- 2007-11-28 SI SI200730682T patent/SI2092069T1/sl unknown
- 2007-11-28 MX MX2009005692A patent/MX2009005692A/es active IP Right Grant
- 2007-11-28 KR KR1020097013421A patent/KR20090102769A/ko not_active Application Discontinuation
- 2007-11-28 JP JP2009538805A patent/JP2010510801A/ja active Pending
- 2007-11-28 BR BRPI0719290-8A patent/BRPI0719290A2/pt not_active IP Right Cessation
- 2007-11-28 CA CA002668932A patent/CA2668932A1/en not_active Abandoned
- 2007-11-28 AU AU2007326985A patent/AU2007326985C1/en not_active Ceased
- 2007-11-28 US US12/515,463 patent/US8119770B2/en not_active Expired - Fee Related
- 2007-11-28 MY MYPI20092137A patent/MY145914A/en unknown
- 2007-11-28 EA EA200970515A patent/EA018700B1/ru not_active IP Right Cessation
- 2007-11-28 AT AT07866627T patent/ATE509106T1/de active
- 2007-11-28 WO PCT/IB2007/004354 patent/WO2008065543A2/en active Application Filing
- 2007-11-28 RS RS20110324A patent/RS51911B/en unknown
- 2007-11-28 EP EP07866627.8A patent/EP2092069B2/en active Active
- 2007-11-28 PT PT07866627T patent/PT2092069E/pt unknown
- 2007-11-28 PL PL07866627T patent/PL2092069T3/pl unknown
- 2007-11-28 TW TW096145220A patent/TW200839012A/zh unknown
- 2007-11-28 DK DK07866627.8T patent/DK2092069T3/da active
-
2009
- 2009-04-30 IL IL198480A patent/IL198480A0/en unknown
- 2009-05-07 CR CR10777A patent/CR10777A/es not_active Application Discontinuation
- 2009-05-08 TN TNP2009000184A patent/TN2009000184A1/fr unknown
- 2009-05-20 GT GT200900137A patent/GT200900137A/es unknown
- 2009-05-25 EC EC2009009361A patent/ECSP099361A/es unknown
- 2009-05-26 SV SV2009003272A patent/SV2009003272A/es unknown
- 2009-05-26 CO CO09053830A patent/CO6190564A2/es not_active Application Discontinuation
- 2009-05-27 NI NI200900097A patent/NI200900097A/es unknown
- 2009-06-24 NO NO20092414A patent/NO20092414L/no not_active Application Discontinuation
- 2009-06-24 MA MA32042A patent/MA31143B1/fr unknown
-
2011
- 2011-07-06 HR HR20110503T patent/HRP20110503T1/hr unknown
- 2011-08-09 CY CY20111100764T patent/CY1112435T1/el unknown
-
2012
- 2012-01-11 US US13/348,297 patent/US8481487B2/en not_active Expired - Fee Related
-
2013
- 2013-06-28 US US13/931,184 patent/US20140030265A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110503T1 (hr) | MODIFICIRANE FUZIJE IZMEĐU TOPIVOG FGF RECEPTORA I Fc, S POBOLJŠANOM BIOLOŠKOM AKTIVNOŠĆU | |
| JP2010510801A5 (es) | ||
| Wester et al. | Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging | |
| Desnoyers et al. | Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models | |
| Ciardiello et al. | Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225 | |
| Ciardiello et al. | Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor | |
| Harding et al. | Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer | |
| Bussolino et al. | Role of soluble mediators in angiogenesis | |
| Gómez-Raposo et al. | Angiogenesis and ovarian cancer | |
| Li et al. | Cell transformation by fibroblast growth factors can be suppressed by truncated fibroblast growth factor receptors | |
| CA3082794A1 (en) | Methods for treatment of bile acid-related disorders | |
| CA3091140A1 (en) | Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer | |
| HUE031122T2 (en) | Preparations and methods for the treatment of cancer based on human FZD receptors | |
| DK1749888T3 (da) | Opløselige Zalph11a-cytokinreceptorer | |
| Askoxylakis et al. | Peptide-based targeting of the platelet-derived growth factor receptor beta | |
| SG188795A1 (en) | Chimeric and humanized anti-cd44 antibodies that mediate cancer cell cytotoxicity | |
| DK1356046T3 (da) | Cytokinreceptor zcytoR19 | |
| CA2361181A1 (en) | Her-2 binding antagonists | |
| Kim et al. | Immunoglobulin Fc-fused, neuropilin-1-specific peptide shows efficient tumor tissue penetration and inhibits tumor growth via anti-angiogenesis | |
| CN106659788A (zh) | 治疗和预防癌症耐药性的方法 | |
| Kim et al. | Characterization, biodistribution and small-animal SPECT of I-125-labeled c-Met binding peptide in mice bearing c-Met receptor tyrosine kinase-positive tumor xenografts | |
| JP2011503039A5 (es) | ||
| Orlova et al. | Pre-clinical evaluation of [111In]-benzyl-DOTA-ZHER2: 342, a potential agent for imaging of HER2 expression in malignant tumors | |
| EP2117593A1 (en) | Cytotoxicity mediation of cells evidencing surface expression of cd44 | |
| Körner et al. | Neuropeptide Y receptors in renal cell carcinomas and nephroblastomas |